David Brister

Aitua Ltd. engages in the commercialization of intellectual properties of companies in the field of life sciences. It provides support to new bio-ventures by investing in the initial stage. The company was founded in June 2006 and is headquartered in Cambridge, the United Kingdom.

AM-Pharma BV operates as a biopharmaceutical company. It engages in the development of proprietary recombinant human Alkaline Phosphatase. The firm’s products include Acute Kidney Injury, Inflammatory Bowel Diseases and Hypophosphatasia. The company was founded in 2001 and is headquartered in Bunnik, the Netherlands.

Veryant, Inc. provides powerful COBOL and Java technology solutions to enable organizations to quickly and safely extend current applications to meet new business needs and demands. The private company is based in Westchester, IL. The company's portable, robust solutions translate into cost-effective, future-proof computing. Veryant's ISCOBOL Evolve enables organizations to retain current COBOL investments while simultaneously offering a path forward to take advantage of the openness, portability, and power of the Java platform without retraining staff or rewriting code.

Crysalin Ltd. develops crysalin lattice technology for protein structure determination. Its portfolio includes crysalins, a protein-based nanotechnology for application in protein structure determination, as well as biosensor development and optoelectronics. The company was founded by Martin Noble and John Sinclair in June 2007 and is headquartered in Oxfordshire, the United Kingdom.

Part of Xention Pharma Ltd., Xention Ltd. is a British company that develops and researches drugs. The company is based in Newmarket, UK. Xention was founded in 2002.

Optimal Medicine Ltd. offers individualized clinical decision support software for mental health disorders. The firm’s products include ADHD care, behavioral health, and rheumatoid arthritis. Its products employ clinical and genetic information about an individual patient to generate information that guides physicians on the treatment for that patient. The company was founded by Janet Munro and Robert McBurney in 2009 and is headquartered in Newcastle-upon-Tyne, the United Kingdom.

OMass Therapeutics Ltd. develops native mass spectrometry platform The company was founded by Dame Carol Robinson and is headquartered in Oxford, the United Kingdom.